InvestorsHub Logo
Followers 0
Posts 11
Boards Moderated 0
Alias Born 10/23/2017

Re: None

Monday, 10/23/2017 5:45:06 PM

Monday, October 23, 2017 5:45:06 PM

Post# of 6389
Biopath estimated range of $3.71-$4.55/share

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)

ACCESSWIREOctober 23, 2017
DALLAS, TX / ACCESSWIRE / October 23, 2017 / Bio-Path Holdings, Inc. (BPTH):
COMPANY DESCRIPTION

News today from Stonegate, they say, (read article below, t'word the bottom it says,) "With promising clinical data and several programs in the pipeline addressing sizable markets with unmet needs, our valuation analysis for the BP1001 for AML and CML programs alone results in an estimated range of $3.71-$4.55/share, with a mid-point of approximately $4.09. See the full report for further details."

https://finance.yahoo.com/news/stonegate-capital-partners-updates-coverage-203000057.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BPTH News